NCT04322890phase 2recruiting

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Hunan Province Tumor Hospital

ClinicalTrials.gov

6000

Enrollment · estimated

Countries · 1 sites

2026-12

Primary completion

1 yr ago

Record updated

Commercial relevance

No explicit biomarker / molecular-testing language identified in the public record.

Biomarker requirement language

4. Oncogenic mutations confirmed by an accredited local laboratory, including EGFR, ALK, ROS1 etc.

Change timeline

No changes detected yet. The first refresh records a baseline snapshot; subsequent refreshes generate field-level changes.

Signals from this trial

New trial
39/100
Opportunity
New phase 2 trial NCT04322890 posted by Hunan Province Tumor Hospital: "Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation".
ClinicalTrials.gov record updated 686 days ago.

Eligibility — raw, for validation

Inclusion Criteria:

1. Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form.
2. Age ≥ 18 years.
3. Histologically or cytologically confirmed, Stage IV NSCLC.
4. Oncogenic mutations confirmed by an accredited local laboratory, including EGFR, ALK, ROS1 etc.
5. ECOG 0-1.
6. Predicted survival ≥ 12 weeks.
7. Adequate bone marrow hematopoiesis and organ function
8. Presence of measurable lesions according to RECIST 1.1.

Exclusion Criteria:

The patient did not match from the Inclusion Criteria.